255 related articles for article (PubMed ID: 16972249)
1. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss.
Botolin S; McCabe LR
J Cell Physiol; 2006 Dec; 209(3):967-76. PubMed ID: 16972249
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of PPARγ increases osteoblastogenesis and bone mass in male C57BL/6 mice.
Duque G; Li W; Vidal C; Bermeo S; Rivas D; Henderson J
J Bone Miner Res; 2013 Mar; 28(3):639-48. PubMed ID: 23044841
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of bisphenol A diglicydyl ether on bone quality and marrow adiposity in ovary-intact and ovariectomized rats.
Li G; Xu Z; Hou L; Li X; Li X; Yuan W; Polat M; Chang S
Am J Physiol Endocrinol Metab; 2016 Dec; 311(6):E922-E927. PubMed ID: 27756728
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of PPARγ by bisphenol A diglycidyl ether ameliorates dexamethasone-induced osteoporosis in a mouse model.
Wang Y; Pan Z; Chen F
J Int Med Res; 2019 Dec; 47(12):6268-6277. PubMed ID: 31709877
[TBL] [Abstract][Full Text] [Related]
5. Caspase-2 deficiency protects mice from diabetes-induced marrow adiposity.
Coe LM; Lippner D; Perez GI; McCabe LR
J Cell Biochem; 2011 Sep; 112(9):2403-11. PubMed ID: 21538476
[TBL] [Abstract][Full Text] [Related]
6. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
Lazarenko OP; Rzonca SO; Suva LJ; Lecka-Czernik B
Bone; 2006 Jan; 38(1):74-84. PubMed ID: 16137931
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic recovery following chemotherapy is improved by BADGE-induced inhibition of adipogenesis.
Zhu RJ; Wu MQ; Li ZJ; Zhang Y; Liu KY
Int J Hematol; 2013 Jan; 97(1):58-72. PubMed ID: 23264188
[TBL] [Abstract][Full Text] [Related]
8. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells.
Bäckesjö CM; Li Y; Lindgren U; Haldosén LA
J Bone Miner Res; 2006 Jul; 21(7):993-1002. PubMed ID: 16813520
[TBL] [Abstract][Full Text] [Related]
9. CCAAT/enhancer binding protein β-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption.
Motyl KJ; Raetz M; Tekalur SA; Schwartz RC; McCabe LR
Am J Physiol Regul Integr Comp Physiol; 2011 May; 300(5):R1250-60. PubMed ID: 21346244
[TBL] [Abstract][Full Text] [Related]
10. BADGE, a synthetic antagonist for PPARγ, prevents steroid-related osteonecrosis in a rabbit model.
Yuan N; Li J; Li M; Ji W; Ge Z; Fan L; Wang K
BMC Musculoskelet Disord; 2018 Apr; 19(1):129. PubMed ID: 29703208
[TBL] [Abstract][Full Text] [Related]
11. Docosahexaenoic acid increases cellular adiponectin mRNA and secreted adiponectin protein, as well as PPARγ mRNA, in 3T3-L1 adipocytes.
Oster RT; Tishinsky JM; Yuan Z; Robinson LE
Appl Physiol Nutr Metab; 2010 Dec; 35(6):783-9. PubMed ID: 21164549
[TBL] [Abstract][Full Text] [Related]
12. Bisphenol A diglycidyl ether induces adipogenic differentiation of multipotent stromal stem cells through a peroxisome proliferator-activated receptor gamma-independent mechanism.
Chamorro-García R; Kirchner S; Li X; Janesick A; Casey SC; Chow C; Blumberg B
Environ Health Perspect; 2012 Jul; 120(7):984-9. PubMed ID: 22763116
[TBL] [Abstract][Full Text] [Related]
13. Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation.
Liu Y; Berendsen AD; Jia S; Lotinun S; Baron R; Ferrara N; Olsen BR
J Clin Invest; 2012 Sep; 122(9):3101-13. PubMed ID: 22886301
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
Ali AA; Weinstein RS; Stewart SA; Parfitt AM; Manolagas SC; Jilka RL
Endocrinology; 2005 Mar; 146(3):1226-35. PubMed ID: 15591153
[TBL] [Abstract][Full Text] [Related]
15. Myeloid Elf-1-like factor stimulates adipogenic differentiation through the induction of peroxisome proliferator-activated receptor γ expression in bone marrow.
Baek K; Cho JY; Hwang HR; Kwon A; Lee HL; Park HJ; Qadir AS; Ryoo HM; Woo KM; Baek JH
J Cell Physiol; 2012 Nov; 227(11):3603-12. PubMed ID: 22307523
[TBL] [Abstract][Full Text] [Related]
16. PPARγ antagonist attenuates mouse immune-mediated bone marrow failure by inhibition of T cell function.
Sato K; Feng X; Chen J; Li J; Muranski P; Desierto MJ; Keyvanfar K; Malide D; Kajigaya S; Young NS
Haematologica; 2016 Jan; 101(1):57-67. PubMed ID: 26589913
[TBL] [Abstract][Full Text] [Related]
17. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice.
Botolin S; Faugere MC; Malluche H; Orth M; Meyer R; McCabe LR
Endocrinology; 2005 Aug; 146(8):3622-31. PubMed ID: 15905321
[TBL] [Abstract][Full Text] [Related]
18. Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice.
Motyl KJ; McCabe LR
J Cell Physiol; 2009 Feb; 218(2):376-84. PubMed ID: 18932203
[TBL] [Abstract][Full Text] [Related]
19. The effects of PPARγ inhibitor on bones and bone marrow fat in aged glucocorticoid-treated female rats.
Fan J; Zhang D; Jiang Y; Yu L; Han B; Qian Z
Exp Gerontol; 2023 Oct; 181():112281. PubMed ID: 37659742
[TBL] [Abstract][Full Text] [Related]
20. Effect of reduced c-Kit signaling on bone marrow adiposity.
Turner RT; Wong CP; Iwaniec UT
Anat Rec (Hoboken); 2011 Jul; 294(7):1126-34. PubMed ID: 21634019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
